ADH-1 + docetaxel

ADH-1 + docetaxel is a combination therapy under investigation for the treatment of various invasive carcinomas, including ovarian cancer. ADH-1 is a synthetic peptide that selectively and competitively binds to and blocks N-cadherin, disrupting tumor vasculature and inducing apoptosis in tumor cells by interfering with cadherin-mediated signaling. This leads to both direct tumor cell death and disruption of blood vessels supporting the tumor. Docetaxel is a taxane-class antineoplastic agent that promotes microtubule assembly while preventing their depolymerization, thereby inhibiting mitosis and leading to cancer cell death. The combination has shown synergistic effects in preclinical models, particularly with taxane-based chemotherapy such as docetaxel[6][4].

Other names

N-cadherin antagonist (for ADH-1)taxoid antineoplastic agent (for docetaxel)